SCD and glioblastoma: Together, these results demonstrate that the SCD inhibitor CAY10566 penetrates the BBB, hits the target, reduces tumor burden, blocks hemorrhage, extends survival of mice with intracranial GBM as a single agent, and improves survival in combination with TMZ relative to TMZ alone.